Search research articles
Contact Us
Filters
Showing results (181-190 of 256) with videos related to
Page
of 26
Sort By:
Journal of Cell Science
|
November 10, 2006
Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway
Jungsug Gwak, Munju Cho, Soo-Jung Gong, et al.
The AAPS Journal
|
January 11, 2019
What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing
Thomas M Polasek, Amin Rostami-Hodjegan, Dong-Seok Yim, et al.
British Journal of Clinical Pharmacology
|
May 5, 2012
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index
Fen Jiang, Zeruesenay Desta, Ji-Hong Shon, et al.
Plos One
|
May 17, 2012
Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition
Im-Sook Song, Do Yup Lee, Min-Hye Shin, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
July 27, 2012
Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism
Wei Pan, Soo-Kyung Bae, Eon-Jeong Shim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 10, 2006
Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A
Kwang-Hyeon Liu, Mi-Gyung Kim, Dong-Jun Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
July 19, 2014
Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers
Ju-Hyun Nam, Minkyung Oh, Hyun Ji Kim, et al.
The Journal of Infectious Diseases
|
October 2, 2025
NAT2 polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living with HIV: Insights from a Pharmacogenetic-Pharmacokinetic Cohort Study
Napon Hiranburana, Jiratchaya Sophonphan, Stephen J Kerr, et al.
Pharmacogenetics and Genomics
|
January 8, 2013
Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals
Fen Jiang, Chang-Woo Yeo, Sang-Seop Lee, et al.
Journal of Clinical Pharmacology
|
November 12, 2013
The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration
Ho-Sook Kim, Doo-Yeoun Cho, Bo-Min Park, et al.
Page
of 26
Search research articles
Search
Showing results (181-190 of 256) with videos related to
Sort By:
Page
of 26
Journal of Cell Science
|
November 10, 2006
Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the Wnt/beta-catenin pathway
Jungsug Gwak, Munju Cho, Soo-Jung Gong, et al.
The AAPS Journal
|
January 11, 2019
What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing
Thomas M Polasek, Amin Rostami-Hodjegan, Dong-Seok Yim, et al.
British Journal of Clinical Pharmacology
|
May 5, 2012
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index
Fen Jiang, Zeruesenay Desta, Ji-Hong Shon, et al.
Plos One
|
May 17, 2012
Pharmacogenetics meets metabolomics: discovery of tryptophan as a new endogenous OCT2 substrate related to metformin disposition
Im-Sook Song, Do Yup Lee, Min-Hye Shin, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
July 27, 2012
Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism
Wei Pan, Soo-Kyung Bae, Eon-Jeong Shim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
August 10, 2006
Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A
Kwang-Hyeon Liu, Mi-Gyung Kim, Dong-Jun Lee, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
July 19, 2014
Pharmacokinetic comparison of amlodipine adipate/valsartan fixed-dose combination with amlodipine besylate/valsartan fixed-dose combination in healthy volunteers
Ju-Hyun Nam, Minkyung Oh, Hyun Ji Kim, et al.
The Journal of Infectious Diseases
|
October 2, 2025
NAT2 polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living with HIV: Insights from a Pharmacogenetic-Pharmacokinetic Cohort Study
Napon Hiranburana, Jiratchaya Sophonphan, Stephen J Kerr, et al.
Pharmacogenetics and Genomics
|
January 8, 2013
Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals
Fen Jiang, Chang-Woo Yeo, Sang-Seop Lee, et al.
Journal of Clinical Pharmacology
|
November 12, 2013
The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration
Ho-Sook Kim, Doo-Yeoun Cho, Bo-Min Park, et al.
Page
of 26